Drugs and patents in ATC class C01E - OTHER CARDIAC PREPARATIONS

Last updated: June 4, 2026

ATC C01E (“Other cardiac preparations”) is a portfolio category rather than a single drug, spanning multiple actives and product types (most commonly ranolazine and vericiguat-adjacent “cardiac” biology, plus select rescue or adjunct cardiac agents in regional formularies). Patent defensibility and generic entry timelines depend on the specific active ingredient, dosage form, and claim set (composition, polymorph/solid state, formulation, method of use, manufacturing process).

This analysis maps the patent-expiration and litigation pressure points that govern pricing power and generic substitution for the dominant marketed C01E drugs in major markets (US, EU5, UK). It also identifies where patent estates tend to be strongest for “evergreening” via solid-state forms, modified-release formulations, and additional indications.

Which drugs belong to ATC C01E “Other cardiac preparations,” and why does the patent picture differ?

ATC C01E is a classification umbrella. The practical patent landscape is determined by whether the category is dominated by (1) small molecules with strong composition/formulation estates, or (2) newer entrants with method-of-use and manufacturing-process claims that can delay ANDA and period-of-exclusivity schedules.

What are the main active ingredients that drive C01E revenue and patent risk?

Across major markets, C01E-linked payer and prescribing volume is typically concentrated in these therapeutic candidates and marketed agents (the exact mix varies by country/formulary):

Ranolazine (antianginal, often the largest C01E-linked small-molecule footprint where included)
Other adjunct cardiac agents depending on regional ATC mapping (some markets fold specific agents under C01E that are not consistently represented under the same label elsewhere)

Patent analysis for C01E therefore must be active-specific. Treat C01E as a “watchlist bucket” for multiple IP estates rather than a single expiration calendar.

How do the patent types differ across typical C01E small-molecule products?

Featured snippet: In C01E, the claim sets that most often block generic entry are (i) composition of matter, (ii) polymorph/solid-state form, (iii) extended/modified-release formulations, and (iv) method-of-use claims tied to dosing regimens or patient subsets.

Common C01E patent stack patterns:

Early-grant composition of matter patents (core active and basic salt/form)
Late-grant solid-state and polymorph patents (new crystals, hydrates, solvates; characterization-heavy)
Formulation and release-profile patents (matrix/film coatings; osmotic systems; ER bead technologies)
Manufacturing-process patents (milling, granulation, solvent systems, heat treatment)
Method-of-use patents (clinical endpoints, patient groups, dose titration)

What patents protect ranolazine and other dominant C01E small-molecule drugs?

Featured snippet: For ranolazine and similar C01E small molecules, the patent estate usually clusters around composition (salt/form), specific solid-state forms, and controlled/modified-release formulation architectures.

Ranolazine patent estate: what claim categories are most common

For ranolazine-type estates, generic blockers tend to be:

Composition of matter (active ingredient and specific salt/form)
Solid-state form patents (polymorphs, hydrates/solvates)
Controlled-release formulation patents (tablets/capsules with defined release kinetics)
Method-of-use patents (adjunct therapy and dosage regimens)

How many patents cover a typical C01E small molecule in the Orange Book?

Portfolio-level reality: the count of Orange Book-listed patents varies widely by product history, but the “generic delay” patents in C01E are often concentrated in:

2 to 5 composition-related patents
3 to 10 formulation/solid-state patents
0 to 5 method-of-use or dosing-related patents
(Exact counts depend on the drug, NDA holder, and amendment history.)

When do C01E drug patents expire in the US and EU, and what are the exclusivity bottlenecks?

Featured snippet: In C01E, the limiting factor is rarely “only patent expiry.” Exclusivity can include regulatory exclusivities that sit next to listed patents and can delay approval even when a single patent expires early.

How to read timing for C01E portfolios

Generic entry timing typically follows this order in practice:

Regulatory exclusivity windows (if applicable to the specific NDA)
Expiration of Orange Book listed patents (composition and formulation)
Likely settlement-triggered launch date
Post-launch patent enforcement against “noninfringing” workarounds

US timing mechanics that drive C01E generic launches

Key mechanics for US ANDA entry:

If the ANDA is filed with Paragraph IV certifications, the applicant becomes eligible for a statutory process that can create a “fast lane” but also invites litigation and 30-month stay risk.
If the brand does not settle early, the 30-month stay often becomes the effective gating event even when some patents are later found invalid or not infringed.

EU timing mechanics

EU outcomes depend on:

patent expiry and whether secondary patents (formulations/solid-state) continue to be in force
supplementary protection certificate (SPC) coverage when available
national injunction practices and “launch overhang” from ongoing litigation

What generic entry risks exist for C01E drugs with polymorph and modified-release patents?

Featured snippet: Polymorph and modified-release patents are high-frequency launch blockers because they are easier to allege infringement against “same active” generics while allowing the brand to assert narrow but enforceable differences in solid-state form and release profile.

Polymorph/solid-state: where infringement arguments typically land

Generic applicants often try to:

use a different polymorph or stable form
adjust particle size distribution
change manufacturing conditions to land on a different crystal habit

Brand leverage:

if claims cover “a solid-state form defined by X-ray diffraction pattern / DSC peaks / habit / impurities,” infringement can still be found even if the generic uses a different nominal process
enforcement focuses on analytical match to the claimed form rather than process similarity

Modified-release formulation: where “workaround” is hardest

For ER or MR products:

patents may claim specific coating layers, matrix compositions, tablet geometries, or release-limiting excipients
generic bioequivalence can coexist with infringement findings because claim scope can cover non-BE parameters like coating architecture and internal structure

Which companies are challenging C01E drug patents via Paragraph IV, and what do settlement patterns look like?

Featured snippet: Paragraph IV challenges cluster among large generic and specialty entrants positioned to fight multi-patent estates, with settlement agreements commonly trading “early” launch in exchange for dismissal or limited launch timing.

Litigation pattern that dominates C01E-type portfolios

Across multi-patent small-molecule estates:

earliest challenges target the most recently listed “secondary” patents (formulation/solid-state)
brands often sue on several patents at once to preserve leverage even if one patent is weak
settlements often include:
- time-based triggers (launch date tied to expiry of a key patent)
- carve-outs for different strengths or dosage forms
- payment or reverse-payment structures in some cases (jurisdiction-specific and deal-conditional)

Risk lens for investors and licensors

A single strong solid-state patent can block the ER product even if composition patents expire.
A weak method-of-use patent can still matter if settlement allows the brand to control a share of the launch timing.

What is the Orange Book status of key C01E products, and how many patents are listed per NDA?

Featured snippet: Orange Book coverage in C01E is typically dense for the brand’s marketed strengths, with multiple patents listed per NDA for different dosage forms and release variants.

How Orange Book listings translate into launch blocking

If multiple patents are active, a generic must certify against each.
Even when a generic successfully “designs around” one patent, remaining listed patents can sustain litigation and delay approval.

What Orange Book patent types matter most

INACTIVE vs ACTIVE status: only active patents block.
“Drug substance” vs “drug product” categories: formulation/solid-state patents often sit in drug product.
“Methods of use” patents: trigger infringement claims based on prescribed usage, sometimes tied to approved dosing.

How do formulation patents in C01E affect bioequivalence and manufacturing/IP barriers?

Featured snippet: Formulation patents can block approval even when generics achieve BE, because claim scope can target manufacturing inputs, release mechanisms, and solid-state characteristics rather than pharmacokinetics alone.

Manufacturing and IP barriers

Common barriers generics face in C01E:

solid-state form control requires specific crystallization conditions
excipient selection and coating process can be part of claims
impurity profile claims can force tighter QC and lead to higher manufacturing cost

What “noninfringing” strategies are commonly attempted

Generic workarounds in solid-state and formulation space typically include:

selecting a different polymorph or hydrate state
changing particle-size and milling parameters
modifying coating system, compression force, or granulation pathway
using different release mechanism architecture (if not covered)

But these strategies can increase cost, reduce yield, and risk failing BE or triggering secondary patents.

How do method-of-use patents change the generic launch calendar for C01E?

Featured snippet: Method-of-use patents can shift the launch calendar by enabling the brand to control labeling and prescribing even after composition/formulation workarounds.

Labeling as a litigation battlefield

In method-of-use settings:

a generic may attempt “section viii carve-out” labeling to avoid infringement
brands argue the generic still induces direct infringement by prescribing for the patented regimen

This can turn launch into a labeling dispute, delaying uptake even when approval is granted.

What patent litigation affects C01E drug commercialization, and where do courts typically focus?

Featured snippet: Courts focus on claim construction, analytical infringement on solid-state/formulations, and whether generic labeling triggers method-of-use infringement theories.

Usual litigation outcomes that matter commercially

invalidation wins on one patent can still leave others in force
“noninfringement” can require costly testing and formulation rework
settlement can cap the litigation tail but lock launch timing

Injunction risk

Brands frequently seek injunctions tied to:

product-specific infringement
continuing infringement for remaining patents
workaround products that fail to truly change the claimed solid-state form or release architecture

How does the C01E competitive landscape evolve after first generic entry?

Featured snippet: After first generic entry in C01E, pricing declines are typically front-loaded, but subsequent share capture depends on whether later entrants can clear the remaining formulation/solid-state patents without relaunch risk.

Post-launch dynamics

early generics may launch “at risk” and later be forced off if injunctions issue
brands may introduce authorized generics or lifecycle extensions (new strengths, ER tweaks) to defend margin
payers switch quickly when multiple AB-rated equivalents exist and when supply is stable

Key takeaways on the C01E patent landscape for R&D, licensing, and litigation strategy

C01E is not a single patent calendar. It is an active-specific set of estates driven by formulation and solid-state claims more than simple composition-only expiries.
Ranolazine-type estates tend to be blocked by secondary patents. Polymorph/solid-state and modified-release formulation patents are frequent “last-mile” barriers to generic entry.
Orange Book density governs risk. Multiple active patents across drug substance, drug product, and methods of use extend litigation and reduce the probability of a clean, early launch.
Paragraph IV strategy is decisive. Generic challengers often select which patents to attack first; brands respond by asserting multiple patents and leveraging settlement leverage.
Workaround feasibility determines commercial upside. Manufacturing and QC constraints tied to solid-state and release-profile claims can be more decisive than BE alone.

FAQs

1) Which patent categories most often delay generic entry for ATC C01E small molecules?
Solid-state (polymorph/hydrate) and modified-release formulation patents most often delay entry even when composition patents are weaker or expired.

2) How can a generic enter without infringing C01E method-of-use patents?
By using labeling carve-outs that avoid the patented regimen and by managing promotion and prescribing risk that can still be argued as inducement.

3) What is the most common “evergreening” mechanism within C01E formulations?
Secondary patents covering crystal forms, impurity-defined solid state, and ER/MR release architectures.

4) When does patent litigation stop mattering commercially in C01E?
After settlement or final resolution clears the last remaining active formulation/solid-state patent and the brand’s injunctive posture ends for the marketed strengths.

5) Does achieving bioequivalence guarantee freedom to operate for C01E?
No. BE does not defeat infringement claims targeting claimed solid-state forms, specific formulation compositions, coatings, or manufacturing-defined characteristics.

References (APA)

No sources were provided or cited in the prompt, and no reliable drug-specific patent/Orange Book dataset was included.

Drugs in ATC Class C01E

Subclasses in ATC: C01E - OTHER CARDIAC PREPARATIONS

ATC Class C01E (Other Cardiac Preparations): Market Dynamics and Patent Landscape for Generics, Biosimilars, and Formulation Patents